<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03368300</url>
  </required_header>
  <id_info>
    <org_study_id>RBM-PAP-2011/86</org_study_id>
    <nct_id>NCT03368300</nct_id>
  </id_info>
  <brief_title>Epidemiology and Pathophysiology of Parkinsonism in the Caribbeans</brief_title>
  <acronym>CAP</acronym>
  <official_title>Epidemiology and Pathophysiology of Parkinsonism in the Caribbeans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Pointe-a-Pitre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Pointe-a-Pitre</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim of this study is to estimate the frequency and to characterize clinically&#xD;
      atypical parkinsonism in the French West Indies and Guyana.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An atypical akineto-rigid parkinsonian syndrome, unresponsive to L-dopa has been evidenced in&#xD;
      Guadeloupe. Abnormally frequent, this progressive supranuclear palsy (PSP)-like syndrome&#xD;
      represents a new clinical entity. Unlike in classical PSP 70% of patients have myoclonus, 59%&#xD;
      hallucinations, 78% REM sleep behavior disorders. Oculomotor pattern differs from classical&#xD;
      PSP suggesting that cortical dysfunction predominates over brainstem impairments.&#xD;
      Neuropathological examination in four patients has shown a widespread accumulation of the tau&#xD;
      protein in the basal ganglia, the midbrain and cortical areas.&#xD;
&#xD;
      This syndrome has been associated to the regular consumption of food products derived from&#xD;
      plants of the Annonaceae family, more specifically Annona Muricata (soursop), suggesting a&#xD;
      toxic origin. We have already confirmed the neurotoxic potential of the lipophilic&#xD;
      mitochondrial complex I inhibitor annonacin, the major acetogenin in Annona muricata. This&#xD;
      class of compounds is specific to Annonaceae. Nanomolar concentrations of annonacin induce&#xD;
      the death of dopaminergic neurons in culture, by impairment of energy production. Chronic&#xD;
      systemic intoxication of rats with annonacin causes neuronal damage in the same brain regions&#xD;
      that are damaged in patients with atypical parkinsonism. These results greatly suggest that&#xD;
      the consumption of annonacea might contribute to the pathogenesis of the disease. The H1&#xD;
      subhaplotype in tau gene associated with PSP in Caucasians did not confer risk for PSP-like&#xD;
      atypical parkinsonism in Guadeloupe.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 3, 2012</start_date>
  <completion_date type="Anticipated">August 3, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 3, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The primary aim of this study is to estimate the frequency and to characterize clinically atypical parkinsonism in the French West Indies and Guyana.&#xD;
This study has been designed as epidemiological, multicentric transversal descriptive and longitudinal prospective study with biological collection and post-mortem neuropathological sub-study of brain tissue.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Not masking, 2 groups parallel</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>to estimate the frequency and to characterize clinically atypical parkinsonism in the French West Indies and Guyana</measure>
    <time_frame>At the end of the Period of inclusion, around 5-6 years</time_frame>
    <description>Collection of :&#xD;
administrative and socioeconomic data, medical consultation with video recording , recording oculomotor to the atypical</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>to compare the proportion of atypical forms within parkinsonian syndromes;</measure>
    <time_frame>At the end of the Period of inclusion, around 5-6 years</time_frame>
    <description>Collection of :&#xD;
administrative and socioeconomic data, medical consultation with video recording , recording oculomotor to the atypical neuropsychological balance assessment ,&#xD;
Clinical diagnostic criteria&#xD;
Compilation of functional indicators of motor and cognitive autonomy and Collection of intercurrent medical events&#xD;
Food and exposure questionnaire&#xD;
Neuropsychological assessment&#xD;
Recording of oculomotor movements and Post-mortem analysis&#xD;
biological collection (plasma, DNA, serum)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>to characterize the entity &quot;Parkinson-dementia complex&quot; described in Guadeloupe ; to characterize the entity &quot;Parkinson-dementia complex&quot; described in Guadeloupe ;</measure>
    <time_frame>Through study completion, an average of 11 years</time_frame>
    <description>Compilation of functional indicators of motor and cognitive autonomy and Collection of intercurrent medical events.&#xD;
Collection of :&#xD;
administrative and socioeconomic data, medical consultation with video recording , recording oculomotor to the atypical neuropsychological balance assessment ,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>to determine the natural history of typical and atypical forms of parkinsonism by following a cohort of the incident cases only;</measure>
    <time_frame>Through study completion, an average of 11 years</time_frame>
    <description>Neuropsychological assessment Food and exposure survey</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>to determine the implication of a toxic alimentary factor in the etiopathogenesis of atypical forms and compare the results in the 3 areas (Guadeloupe, Guyane, Martinique);</measure>
    <time_frame>Through study completion, an average of 11 years</time_frame>
    <description>Neuropsychological assessment Food and exposure survey</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>to determine the latency of cognitive decline in idiopathic Parkinson's disease in the 3 areas ;</measure>
    <time_frame>Through study completion, an average of 11 years, post-mortem analysis after death if applicable</time_frame>
    <description>Recording of oculomotor movements and Post-mortem analysis (sampling of blood and cutaneous biopsy to establish a collection of biological samples)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>to constitute a biological collection (plasma, DNA, serum).</measure>
    <time_frame>At the end of the Period of inclusion, around 5-6 years</time_frame>
    <description>biological collection (plasma, DNA, serum)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">550</enrollment>
  <condition>Atypical Parkinsonism</condition>
  <arm_group>
    <arm_group_label>Patients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Parkinson's patient</description>
  </arm_group>
  <arm_group>
    <arm_group_label>witnesses: without parkinson's disease</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects without parkinson's disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Clinical and biological exam</intervention_name>
    <description>The study will include a clinical, neuropsychological, oculomotor, food intake and environmental exposure assessment. Blood samples will be taken to constitute a library of plasma, DNA and serum. The harvesting of samples will be part of a subsequent study. Consent for possible post-mortem neuropathological analysis will be proposed.&#xD;
All the patients accepting it will be followed by a 5-year longitudinal follow-up. The longitudinal follow-up bi-annual and then annual will include a clinical evaluation, a questionnaire of dependence and a questionnaire of monitoring of exposure to certain environmental factors&#xD;
All controls must answer a questionnaire of environmental exposure factors, oculomotor test, and blood sample (3 collections: DNA, serum, plasma).</description>
    <arm_group_label>Patients</arm_group_label>
    <arm_group_label>witnesses: without parkinson's disease</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pour les patients :&#xD;
&#xD;
               1. Patient ou tiers responsable ayant reçu une information sur l'étude et ayant&#xD;
                  signé le consentement éclairé&#xD;
&#xD;
               2. Patient âgé de plus de 18 ans&#xD;
&#xD;
               3. Patient consultant en neurologie ou en gériatrie pour symptomatologie&#xD;
                  parkinsonienne ou pour troubles cognitifs évocateurs d'une démence à corps de&#xD;
                  Lewy&#xD;
&#xD;
               4. Patient domicilié aux Antilles-Guyane&#xD;
&#xD;
                  Pour les témoins :&#xD;
&#xD;
               5. Conjoint ou accompagnant ayant reçu une information sur l'étude et ayant signé le&#xD;
                  consentement éclairé&#xD;
&#xD;
               6. Personne âgée de plus de 18 ans&#xD;
&#xD;
               7. Personne ne présentant pas de pathologie d'allure neurodégénérative (Parkinson,&#xD;
                  démence notamment)&#xD;
&#xD;
               8. Personne domiciliée aux Antilles-Guyane&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Pour les patients :&#xD;
&#xD;
          1. Syndrome parkinsonien secondaire (post-traumatique, vasculaire, iatrogène, post&#xD;
             encéphalitique)&#xD;
&#xD;
          2. Patient non affilié au régime de sécurité sociale&#xD;
&#xD;
          3. En cas de difficulté de suivi le patient sera exclu de l'étude longitudinale&#xD;
&#xD;
        Pour les témoins :&#xD;
&#xD;
          1. Personnes présentant des troubles cognitifs ou un syndrome parkinsonien diagnostiqué.&#xD;
&#xD;
          2. Patient non affilié au régime de sécurité sociale -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Annie LANNUZEL, PU-PH</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital of Guadeloupe</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Régine EDRAGAS, PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Martinique</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dominique MARNET, PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>: University Hospital of Guyana</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Valérie HAMONY SOTER, Project leader</last_name>
    <phone>0590 93 46 86</phone>
    <phone_ext>+590</phone_ext>
    <email>valerie.soter@chu-guadeloupe.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mélanie PETAPERMAL, Monito manager</last_name>
    <phone>0590 93 46 86</phone>
    <phone_ext>+590</phone_ext>
    <email>melanie.petapermal@chu-guadeloupe.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital of Guyana</name>
      <address>
        <city>Cayenne</city>
        <zip>97306</zip>
        <country>French Guiana</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominique MARNET, PH</last_name>
      <phone>05 94 39 51 46</phone>
      <phone_ext>(+0594)</phone_ext>
      <email>domminique.marnet@ch-cayenne.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Martinique</name>
      <address>
        <city>Fort-de-France</city>
        <zip>97261</zip>
        <country>Martinique</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Régine EDRAGAS, PH</last_name>
      <phone>05 96 720482</phone>
      <phone_ext>(+596)</phone_ext>
      <email>nakapmireil@yahoo.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>French Guiana</country>
    <country>Martinique</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <study_first_submitted>November 24, 2017</study_first_submitted>
  <study_first_submitted_qc>December 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2017</study_first_posted>
  <last_update_submitted>December 5, 2017</last_update_submitted>
  <last_update_submitted_qc>December 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>progressive supranuclear palsy</keyword>
  <keyword>Caribbean atypical Parkinsonism</keyword>
  <keyword>Annona Muricata</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinsonian Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

